Guidelines for management of Bowen's disease: 2006 update.
This article represents a planned regular updating of the previous British Association of Dermatologists (BAD) guidelines for management of Bowen's disease. They have been prepared for dermatologists on behalf of the BAD. They present evidence-based guidance for treatment, with identification of the strength of evidence available at the time of preparation of the guidelines.
Cox
N H
NH
Craigavon Area Hospital, Craigavon BT63 5QQ, U.K. neil.cox@ncumbria-acute.nhs.uk
Eedy
D J
DJ
Morton
C A
CA
D000276:Adjuvants, Immunologic; D000634:Aminoquinolines / Q000627:therapeutic use; D001913:Bowen's Disease / Q000209:etiology / Q000628:therapy*; D002425:Cautery / Q000379:methods; D017679:Cryotherapy / Q000379:methods; D003475:Curettage / Q000379:methods; D018450:Disease Progression; D019317:Evidence-Based Medicine / Q000706:statistics & numerical data; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D000077271:Imiquimod; D007165:Immunosuppression Therapy / Q000379:methods; D053685:Laser Therapy / Q000379:methods; D010778:Photochemotherapy / Q000379:methods; D012307:Risk Factors; D012878:Skin Neoplasms / Q000532:radiotherapy / Q000628:therapy*
D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D000077271:Imiquimod; D005472:Fluorouracil